Historical Valuation
Boston Scientific Corp (BSX) is now in the Fair zone, suggesting that its current forward PE ratio of 28.52 is considered Fairly compared with the five-year average of 27.14. The fair price of Boston Scientific Corp (BSX) is between 86.72 to 110.79 according to relative valuation methord.
Relative Value
Fair Zone
86.72-110.79
Current Price：98.38
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Boston Scientific Corp (BSX) has a current Price-to-Book (P/B) ratio of 6.00. Compared to its 3-year average P/B ratio of 5.45 , the current P/B ratio is approximately 10.17% higher. Relative to its 5-year average P/B ratio of 4.71, the current P/B ratio is about 27.49% higher. Boston Scientific Corp (BSX) has a Forward Free Cash Flow (FCF) yield of approximately 2.72%. Compared to its 3-year average FCF yield of 1.81%, the current FCF yield is approximately 50.51% lower. Relative to its 5-year average FCF yield of 1.88% , the current FCF yield is about 44.75% lower.
P/B
Median3y
5.45
Median5y
4.71
FCF Yield
Median3y
1.81
Median5y
1.88
Competitors Valuation Multiple
AI Analysis for BSX
The average P/S ratio for BSX competitors is 7.33, providing a benchmark for relative valuation. Boston Scientific Corp Corp (BSX.N) exhibits a P/S ratio of 6.47, which is -11.83% above the industry average. Given its robust revenue growth of 20.34%, this premium appears sustainable.
Performance Decomposition
AI Analysis for BSX
1Y
3Y
5Y
Market capitalization of BSX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BSX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BSX currently overvalued or undervalued?
Boston Scientific Corp (BSX) is now in the Fair zone, suggesting that its current forward PE ratio of 28.52 is considered Fairly compared with the five-year average of 27.14. The fair price of Boston Scientific Corp (BSX) is between 86.72 to 110.79 according to relative valuation methord.
What is Boston Scientific Corp (BSX) fair value?
BSX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Boston Scientific Corp (BSX) is between 86.72 to 110.79 according to relative valuation methord.
How does BSX's valuation metrics compare to the industry average?
The average P/S ratio for BSX's competitors is 7.33, providing a benchmark for relative valuation. Boston Scientific Corp Corp (BSX) exhibits a P/S ratio of 6.47, which is -11.83% above the industry average. Given its robust revenue growth of 20.34%, this premium appears sustainable.
What is the current P/B ratio for Boston Scientific Corp (BSX) as of Jan 09 2026?
As of Jan 09 2026, Boston Scientific Corp (BSX) has a P/B ratio of 6.00. This indicates that the market values BSX at 6.00 times its book value.
What is the current FCF Yield for Boston Scientific Corp (BSX) as of Jan 09 2026?
As of Jan 09 2026, Boston Scientific Corp (BSX) has a FCF Yield of 2.72%. This means that for every dollar of Boston Scientific Corp’s market capitalization, the company generates 2.72 cents in free cash flow.
What is the current Forward P/E ratio for Boston Scientific Corp (BSX) as of Jan 09 2026?
As of Jan 09 2026, Boston Scientific Corp (BSX) has a Forward P/E ratio of 28.52. This means the market is willing to pay $28.52 for every dollar of Boston Scientific Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Boston Scientific Corp (BSX) as of Jan 09 2026?
As of Jan 09 2026, Boston Scientific Corp (BSX) has a Forward P/S ratio of 6.47. This means the market is valuing BSX at $6.47 for every dollar of expected revenue over the next 12 months.